VivoSeq
Respiratory

Obstructive Sleep Apnea

131

Pipeline Programs↗

37

Active Trials↗

54

Companies Involved↗

Obstructive Sleep Apnea is a highly competitive landscape with 131 programs across 54 companies. The most active players are Johnson & Johnson, Retrophin, Boehringer Ingelheim. 39 therapies are approved with 24 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

43/100

Mech. Concentration

8/100

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1R

Retrophin

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1I

INSYS Therapeutics Inc

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

3 programs

Phase 1Bayer logo

Bayer

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

138 of 146 classified programs — the dominant modality here.

5%ALL OTHERSPeptide53%Monoclonal antibody1<1%Protein / enzyme1<1%Vaccine1<1%

Small molecule leads; the ring shows all 146 classified programs, each share of the total. Modality classified for 99% of 150 pipeline programs.

Analysis

Trial Status

165

clinical trials

Completed95 · 58%
Recruiting26 · 16%
Unknown status13 · 8%
Withdrawn9 · 5%
Terminated9 · 5%
Not yet recruiting9 · 5%
Other4 · 2%

Clinical Trials

Trial Activity

165 trials

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
Recruiting·Amgen logoAmgen·Phase 3·NCT07226765·250 enrolled
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine
Recruiting·—·Phase 1·NCT03860233·40 enrolled
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
Recruiting·UUniversity of Arizona·Phase 2·NCT05933603·36 enrolled
Dexmedetomidine Versus Propofol Sedation for Drug-Induced Sleep Endoscopy in Pediatric Obstructive Sleep Apnea
Recruiting·—·Phase 2·NCT05303987·90 enrolled
OROPHARYNGEAL MYOFUNCTIONAL THERAPY IN OBSTRUCTIVE SLEEP APNEA
Recruiting·IInstituto de Investigación Marqués de Valdecilla·Phase 3·NCT06681974·30 enrolled
Stellate Ganglion Block in Obstructive Sleep Apnea
Recruiting·—·N/A·NCT06249490·80 enrolled
EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION
Recruiting·UUniversity Hospital, Rouen·Phase 2·NCT06462287·24 enrolled
CPAP Effect on the Polycythemia in Patients With Obstructive Sleep Apnea
Recruiting·HHospital Universitario Ramon y Cajal·Phase 4·NCT06089603·182 enrolled
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 3·NCT06994650·140 enrolled
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Recruiting·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06931028·260 enrolled
Impact of Obstructive Sleep Apnea (OSA) Treatment on Blood Pressure Control in Chronic Kidney Disease
Recruiting·UUniversity of Sao Paulo·Phase 4·NCT05846490·150 enrolled
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Recruiting·Amgen logoAmgen·Phase 3·NCT07225686·250 enrolled
Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics
Recruiting·—·Phase 4·NCT04991389·120 enrolled
Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea
Recruiting·SShanghai Fengxian District Central Hospital·N/A·NCT07281196·15 enrolled
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 3·NCT06974851·140 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)